CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 25 target
Drug / intervention
Antithymocyte globulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00488436
NCT00488436Phase 4Completed
CompareCT.gov

SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome

PETHEMA Foundation·interventional·Posted Jun 20, 2007·Updated Nov 19, 2008

In Brief

A Phase 4 clinical trial evaluating Antithymocyte globulin and Cyclosporine for Myelodysplastic Syndrome. Completed, enrolled 25 participants across 11 sites.

Detailed Summary

The different mechanisms of action between Antithymocyte globulin and cyclosporine can improve the effectivity when both are used in combination in patients with myelodysplastic syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndrome
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2007
Enrollment StartMay 1, 2002
Primary CompletionJun 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 19.0 years ago

Interventions

Antithymocyte globulindrug

Cyclosporinedrug